Brandon Mancini, MD, MBA, FACRO

Sandra Turner, MBBS, PhD, shared ideas for radiation oncology teams to engage locally with World Radiotherapy Awareness Day.

Sandra Turner, MBBS, PhD, outlined the global radiotherapy access gap stretching from Australia to sub-Saharan Africa.

Sandra Turner, MBBS, PhD, explained why September 7, radiotherapy’s first modern linac milestone, was chosen for World Radiotherapy Awareness Day.

Radiopharmaceutical therapy currently falls somewhere between localized treatment and systemic therapy, according to Mallika Marar, MD, MBA.

Experts highlight the origins and significance of World Radiotherapy Awareness Day and discuss global access challenges surrounding modern radiation oncology.

Rethinking dose fractions and managing subclinical renal and marrow toxicity represent ongoing challenges associated with the use of radiopharmaceutical therapy.

Experts discussed the rapidly expanding radiopharmaceutical paradigm and how to integrate such technology into real-world oncology practice.

Experts discuss how to navigate coding, reimbursement, and other potential financial strains when treating patients via radiotherapy.

The latest conversation in RadOnc on the Run explores patient and provider considerations for navigating cancer diagnosis, treatment, and recovery.

Host Brandon Mancini, MD, MBA, FACRO, discusses stereotactic radiosurgery, proton therapy, and other relevant modalities in the management of brain tumors.

Experts outline technological advances, treatment de-escalation strategies, and lifestyle factors that may affect treatment for head and neck cancers.

Experts discuss the evolution of rectal cancer care from the use of “cookie cutter” approaches to the growth of personalized treatment pathways.

Looking ahead, local therapies and biomarkers may become even more important in the management of kidney cancer.

Host Brandon Mancini, MD, MBA, FACRO, discusses presentations from ASCO GU 2026 featuring potential advances in the use of radiotherapeutic regimens.

Experts review strategies for effective screening and other measures for limiting cancer incidence in observance of National Cancer Prevention Month.

Experts outline current initiatives from the American College of Radiation Oncology as well as potential next steps for advancing the field.

Theranostics is an escalating field within radiation oncology and clinicians should be utilizing it every day, according to Brandon Mancini, MD, MBA, FACRO.

Experts discuss new modalities such as HPV vaccines, balancing hope with realism, and other considerations in cervical cancer management.

Host Brandon Mancini, MD, MBA, FACRO, introduces a special podcast series focused on delivering key insights and takeaways in the radiation oncology space.

Brandon R. Mancini, MD, MBA, FACRO, discussed results from a phase 1/2a trial that evaluated [212Pb]VMT-α-NET in patients with advanced NETs.

Panelists discuss how PSMA PET imaging is expected to evolve, enhancing precision in prostate cancer treatment through improved detection and staging. Medical professionals anticipate broader use in therapy guidance, with future advancements addressing gaps in early detection and metastasis, improving treatment strategies.

Panelists discuss how, Copper-64 (^64Cu)–labeled PSMA-targeted PET imaging is emerging as a promising modality in prostate cancer diagnosis. The phase 2 SOLAR study (NCT05653856) demonstrated that ^64Cu-PSMA I&T PET/CT effectively detects metastatic prostate cancer, meeting primary end points related to correct localization rates. Compared with gallium-68 (^68Ga) and fluorine-18 (^18F), ^64Cu offers a half-life of approximately 12.7 hours, facilitating centralized production and distribution, which may improve accessibility

Panelists discuss how PSMA PET imaging identified a region of high tracer uptake, guiding medical professionals to implement a focal radiation boost. This approach improved treatment precision and targeting of aggressive areas, highlighting the potential for personalized, effective therapies.

Panelists discuss how PSMA PET imaging has significantly influenced prostate cancer management by enabling precise detection of metastatic lesions, thereby informing and altering treatment strategies. For instance, a study demonstrated that ^68Ga-PSMA-11 PET/CT impacted definitive radiation therapy (RT) planning in 16.5% of patients, leading to modifications in RT fields based on the imaging findings.

Panelists discuss how PSMA PET imaging is increasingly utilized to assess treatment response in prostate cancer, offering superior accuracy over PSA monitoring alone. Incorporating PSMA PET into clinical practice involves considering factors such as timing post treatment and the specific clinical scenario. For instance, studies have demonstrated that PSMA PET/CT can detect intraprostatic and metastatic lesions even at very low PSA levels during treatment monitoring.

Panelists discuss how, PSMA PET imaging significantly enhances surgical decision-making in prostate cancer by precisely identifying tumor location, extent, and metastatic spread with superior sensitivity compared to conventional imaging. This molecular targeting enables more accurate surgical planning, improved patient selection for radical prostatectomy versus targeted approaches, and better identification of lymph node involvement, ultimately allowing for personalized treatment strategies that maximize oncological outcomes while minimizing unnecessary interventions.

Panelists discuss how PSMA PET imaging plays a crucial role in detecting biochemical recurrence of prostate cancer, offering superior sensitivity and specificity compared with conventional imaging methods. In clinical practice, PSMA PET is typically ordered when there is a rise in prostate-specific antigen (PSA) levels post treatment, indicating potential recurrence. The imaging results significantly influence treatment decisions such as distinguishing between localized salvage therapy and systemic treatments. Pivotal trials have demonstrated the efficacy of various tracers.

Panelists discuss how PSMA PET imaging plays a crucial role in the initial staging of prostate cancer, offering superior accuracy over conventional methods. Medical professionals consider factors such as diagnostic performance, tracer availability, and patient-specific characteristics when selecting appropriate PSMA PET agents. The integration of PSMA PET findings into clinical practice has led to more precise treatment planning, potentially improving patient outcomes. Pivotal trials have demonstrated the efficacy of various PSMA PET tracers in detecting prostate cancer metastases.

Panelists discuss how high-quality imaging is crucial for accurately staging prostate cancer, guiding treatment decisions, and optimizing patient outcomes. Superior resolution and sensitivity of PSMA PET tracers enhance lesion detection, influencing surgical, radiation, and systemic therapy choices. Differences in tracer properties impact specificity, affecting treatment planning. Advanced imaging reduces uncertainty, improving risk stratification and therapeutic precision.